The polymorphism of species A rotavirus genotype G1 strains (RVA-G1) circulating in Rio de Janeiro between 1996 and 2004 was evaluated. The VP7 encoding gene of 36 G1 isolates was sequenced and compared to references strains. The deduced amino acid sequences were used as basis for in silico analysis of the VP7 protein. We observed the circulation of two major G1 lineages and five sublineages during the studied period. Comparison between the VP7 trimeric structures of a rotavirus vaccine strain and Brazilian G1 strains showed mutations at amino acid residues located at the calcium binding site and at several neutralizing antibody recognition sites. Although the rotavirus vaccine program has clearly been successful in Brazil, these results suggest the possibility of the emergence of G1 strains that could evade the immune response elicited by a RVA vaccine and cause a vaccine breakthrough. Consequently, continuous monitoring of rotavirus intragenotypes diversity is critical to understand how it could affect vaccine effectiveness.
Rotaviruses (RVs) are members of the Reoviridae family, and classified into seven species (A-G) commonly referred to as ''RVs groups'' (Matthijnssens et al., 2011) . Rotaviruses species A (RVA) are the main etiologic agents of acute gastroenteritis and responsible for nearly 400,000 deaths worldwide (Parashar et al., 2006) . The viral genome consists of 11 segments of double-stranded (ds) RNA encoding six structural proteins (VP) and five or six (depending on the strain) non-structural proteins (NSP) (Matthijnssens et al., 2011) . The genome is enclosed within a three-layered particle. The inner layer consists of VP2, which encloses the genome, and the two minor structural proteins VP1 and VP3, thus forming the core. The middle layer, which consists of VP6, surrounds the core, forming a doubly layered particle (DLP). The outer layer, consisting of VP7 and spike-like projections of VP4, encloses the DLP and completes the three-layered particle (TLP) or infectious virion (Estes and Kapikian, 2007) .
The outer capsid proteins VP7 and VP4 carry independent neutralization and protective antigens and antibodies to either protein can confer resistance to virulent rotavirus in a type-specific man-ner in experimental animals (Estes and Kapikian, 2007) . A binary system is used to classify RVA into P and G genotypes based on the specificity of the VP4 and VP7-encoding genes, respectively (Estes and Kapikian, 2007) . Thus far, 35 P genotypes and, 27 G genotypes have been identified (Matthijnssens et al., 2011) .
The mechanisms driving rotavirus diversification include intersegmental recombination, rearrangement, and reassortment (Gouvea and Brantly, 1995; Desselberger, 1996; Suzuki et al., 1998; Iturriza-Gómara et al., 2001; Estes and Kapikian, 2007) . Genetic and antigenic diversity of viruses are generally driven by immunologic selection. Point mutations are often described for RVA and these mutations eventually can lead to the emergence of virus strains that can escape neutralization by specific antibodies (Dyall-Smith et al., 1986; Ciarlet et al., 1997) . Crystal structure of VP7 showed that it is a trimer stabilized by two Ca 2+ ions bound at each subunit interface of the trimer (Dormitzer et al., 2000; Aoki et al., 2009 ). Uncoating of VP7, probably by withdrawal of Ca 2+ dissociates the VP7 trimer and initiates penetration-inducing conformational changes in the VP4 protein (Aoki et al., 2009) . Neutralizing antibodies against VP7 can stabilize the trimer inhibiting the uncoating trigger for VP4 rearrangement (Aoki et al., 2009) . The VP7 gene encodes 326 amino acids and carries nine variable regions (VR1-VR9) highly divergent across the G genotypes. Four of these regions A (aa 87-101), B (aa 141-151), C (aa 208-224) and F (aa 235-242) have been shown to be of antigenic importance (Dyall-Smith et al., 1986; Ciarlet et al., 1997) . Antigenic regions A and C are mainly involved in virus neutralization, and together form a conformational antigenic site, in which different epitopes correlate functionally with each other (Kobayashi et al., 1991) . Structural reconstruction of VP7 have shown that mutation in this protein permit escape from neutralization by various monoclonal antibodies mapped to two regions named 7-1, which is immunodominant and includes several epitopes into the conformational antigenic site formed by the antigenic regions A and C and, region 7-2 that includes mostly epitopes located in the antigenic region B (Aoki et al., 2009) . Moreover, molecular analysis has demonstrated the existence of at least nine different lineages and thirteen sublineages of human RVA-G1 strains that either alternate or co-circulate in the population (Parra et al., 2005; Arista et al., 2006; Phan et al., 2007; Arora et al., 2009) .
Two RVA vaccines have recently been introduced in several countries. Rotateq Ò (Merck and Co., Witehouse Sation, NJ, USA) is an oral pentavalent rotavirus vaccine consisting of 5 human-bovine reassortants carrying the VP7 genes of human G1, G2, G3 and G4 and VP4 gene of human P [8] . Rotarix Ò (GlaxoSmithKline, Genval, Belgium) is a monovalent vaccine composed of an attenuated human rotavirus strain G1P [8] . Both vaccines contains G1 strains that were isolated in the 80s'; strain 82-12 isolate in 1988 (Ward and Bernstein, 2009 ) is the parental strain of Rotarix Ò vaccine [Rotarix Ò , RVA/Vaccine/USA/Rotarix-A41CB052A/1988/ G1P1A[8]) and strain WI79 isolate in 1983 was used to generate the WI79-9 reassortant contained in the Rotateq Ò vaccine in 1992 (Rotateq Ò , RVA/Vaccine/USA/RotaTeq-WI79-9/1992/G1P7 [5]) (Matthijnssens et al., 2010) . A RVA vaccine candidate, the HRV-BRV vaccine, is an oral pentavalent vaccine containing five human-bovine reassortant carrying the VP7 genes of human G1-G4 and G9. The serotype 1 strain (D strain) isolated in 1974 (Wyatt et al., 1983 ) was used to generate the DxUK reassortant in this vaccine in 1984 (RVA/Vaccine/USA/HRV-BRV-DxUK/1984/G1P7[5]) (Midthun et al., 1985; Kapikian et al., 2005) .
Antigenic and genomic variations have been demonstrated for both neutralizing antigens (VP4 and VP7) of RVA, particularly among the six most common genotypes G1-G4, G9 and P[8] which are the main targets for vaccine development (Santos and Hoshino, 2005) . The effects of such variations on the efficacy of these vaccines are yet to be determined. However, based on serological (Green and Kapikian, 1992; O'Ryan et al., 1994; Jin et al., 1996) and molecular studies (Parra et al., 2005; Arista et al., 2006; Rodríguez-Castillo et al., 2006; Phan et al., 2007; Arora et al., 2009; Arora et al., 2011) it is reasonable to speculate that these variations could be responsible for vaccine breakthrough, forcing a reassessment of the strategies for vaccine production.
In 2006, the Brazilian Ministry of Health introduced the monovalent G1P[8] (Rotarix Ò ) vaccine in its national immunization program. Therefore, it is vital to monitor the emergence of G1 variants strains that could escape the vaccine-induced immunity in the country. Herein, we describe the genetic evolution of RVA-G1 strains detected in Brazil during a nine years period and discus its possible implication on the efficacy of a RVA vaccine program.
Materials and methods

Ethics
The Ethics Committees of the Hospital Universitário Clementino Fraga Filho, and the Instituto de Puericultura e Pediatria Martagão Gesteira of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, approved the study protocol.
Stool specimens
A total of 91 stool specimens collected between January 1996 and December 2004 from Brazilian children <5 years old with acute diarrhea that had been shown to be positive for rotavirus G1P[8] (Benati et al., 2010) were included in this study. The human strain RVA/Human-tc/USA/Wa/1974/G1P1A[8] was used as prototype for RVA G1P[8] in all experiments.
RNA extraction and RT-PCR amplification
The viral dsRNA was extracted from stools using the Totally RNA Kit (Applied Biosystems/Ambion, Austin, TX) according to the manufacturer's recommendations, and subjected to reverse transcription followed by PCR using the Beg9-End9 primers (Gouvea et al., 1990) .
Sequencing and phylogenetic analysis
The amplified cDNAs of 36 G1 strains purified using the Wizard SV Gel and PCR Clean Up System (Promega, Madison, WI), and the sequences were determined with the BigDye terminator cycle sequencing kit and the ABI PRISM 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA). The primers used for sequencing were Beg9, End9 (Gouvea et al., 1990) , and VP71F -T GTATTATCCAACTGAAGC, VP74F -TTATCCAACAATCGGGAGAA, VP 75F -GAATTTCCGTCTGGCTAAC, VP70R -TGGATAATACAAACA-TAAT, and VP72R -TATTCCTAACGTTTGTGTAT selected in this study. The DNA sequences were assembled and analyzed with the programs SeqMan, EditSeq, and MegAlign in the Lasegene software package (DNASTAR, Madison, WI). The phylogenetic analysis was carried out with MEGA software, version 5.0 (Kumar et al., 2004) . Distances were corrected using the Jukes-Cantor model and the phylogenetic tree was constructed using the neighborjoining method. The statistical significance was estimated by bootstrap analysis with 1,000 pseudoreplicates. The sequences were compared to that of G1 rotavirus strains obtained from the Gen-Bank (RVA/Vaccine/USA/Rotarix -A41CB052A/1988/G1P1A[8] -2.5. Prediction of 3D structure of VP7 protein and comparative analysis A similarity search was carried out in the Protein Data Bank (PDB) (http://www.ncbi.nlm.nih.gov/protein) using BLASTP (Altschul et al., 1990) to find suitable templates. The structure of the VP7 protein from a simian rotavirus complexed with an antibody was downloaded from PDB database by entering PDB ID code 3FMG (Aoki et al., 2009) , and used as template for comparative modeling. The 3D structures of VP7 were modeled individually using the windows version of MODELLER 9v8 (Eswar et al., 2006) which can be accessed freely from their website http://salilab.org/modeller. The modeled structures were subjected to analysis by Ramachandran plots generated by PROCHECK freely accessed at http:// www.ebi.ac.uk/thornton-srv/software/PROCHECK and, further validation was employed using ProSA (Wiederstein and Sippl, 2007) accessible at http://prosa.services.came.sbg.ac.at. The root mean square deviation (RMSD) of the backbone atoms (Carbon) was calculated using the program PyMOL which was also used for molecular structure visualization (http://pymol.org/).
Results
Sequencing and phylogenetic analysis
The complete VP7 coding sequence of 36 G1 strains was determined. Phylogenetic analysis of the nucleotide sequences showed that the Brazilian G1 strains clustered into two G1 lineages (G1-I and G1-II) and five sublineages (Ia, Ib, Ic, IIc and IId). A co-circulation of the lineages was observed throughout the study. None of our samples clustered with either vaccine strain RVA/Vaccine/ USA/Rotarix-A41CB052A/1988/G1P1A[8] that belong to sublineage G1-IIa, vaccines strains (RVA/Vaccine/USA/RotaTeq-WI79-9/1992/ G1P7[5] and RVA/Vaccine/USA/HRV-BRV-DxUK/1984/G1P7[5]) or the reference strain (RVA/Human-tc/USA/Wa/1974/G1P1A [8] ) that belong to lineage G1-III (Fig. 1) . Likewise, comparison of VP7 sequences of Brazilian strains isolated in Rio de Janeiro (Araújo et al., 2007) and São Paulo (Carmona et al, unpublished data) between 1996 and 2004 as well as South American strains isolated between 1996 and 2005 obtained from the GenBank did not cluster with vaccine strains, except for two strains from Paraguay isolated in 1996 that clustered with the Rotarix vaccine. On the other hand, two Brazilian strains, Brz-3 and Brz-5 isolated in 1991 and 1992, respectively, from placebo controls participating in a rotavirus vaccine trial in Belém (Jin et al., 1996) clustered in lineage III together with DxUK and WI79-9 vaccine strains (Fig. 1) .
The degree of nucleotide identity among the Brazilian strains within each lineage was >95.3% and 97.6% for lineages I and II, respectively. The identity between the lineages I and II ranged from 93.9% to 95.0%. When compared to the lineage of vaccine strains this identity ranged from 90.5% to 98.7% The amino acid identity within each lineage was >96.0% and 98.2% for lineages I and II, respectively. The percentage between lineages was from 93.9% to 96.0%. When compared to the lineage of reference strains identity ranged from 95.1% to 98.5%.
The majority of the amino acid changes between the Brazilian G1 strains from both lineages (I and II) and G1 reference strains (lineage III) occurred within the hypervariable regions, including the antigenic regions A-C (Fig. 2) .
3D structure and comparative analysis
The 3D models generated in our analysis exhibited good stereochemical qualities, with more than 99% of its residues within allowed regions of the Ramachandran plot. The RMSD measures the structural similarity between optimally superposed structures, and is used as indicative of the model quality. The highest RMSD between each model and 3FMG was 0.27 Å. The ProSa Z-score measures the deviation of the total energy of a structure of interest in regard to an energy distribution derived from random conformations. The Z-scores of the generated VP7 models ranged from À7.42 to À7.39. Those values are in agreement with the scores of proteins with similar size ($230 residues), indicating that the models have no major errors.
The proteins were modeled in their trimeric forms using the biological unit of 3FMG. The VP7 trimer is stabilized by calcium ions located at the interfaces of the subunits (Aoki et al., 2009 ). The regions on VP7, 7-1 and 7-2, are located at the exposed surfaces of the calcium binding sites, or between domains from the same subunit (Aoki et al., 2009) , as exemplified in Fig. 3 . Comparison between the VP7 trimeric structures of the vaccine strain RVA/ Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] and the Brazilians G1 strains showed mutations at amino acid residues located at the calcium binding site (aa 231 Asp ? Asn) and at the antibody recognition sites (aa 94 [Asn ? Ser], 217 [Met ? Thr or Met ? Ile]; and 291 [Lys ? Arg]) ( Fig. 4) .
Amino acid residues known to contribute to calcium ligation in the simian rotavirus 3D protein 3FGM (aa 177, 182, 206, 214, 216, 228, 229 and 231) (Aoki et al., 2009 ) were found to be conserved and placed in equivalent spacial positions on the models in comparison with vaccine strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/ G1P1A[8], with exception of the 231-Asp ? Asn mutation in lineage G1-Ia (Fig. 2) . The residues proposed as integrin binding site (aa 253-255) (Aoki et al., 2009 ) and as possible glycosylation sites of the VP7 protein (aa 69-71 and aa 238-240) (Jayasinghe and Palombo, 1999) remained conserved among all Brazilians contemporary strains analyzed in this study.
Discussion
Several studies have investigated the genetic variation of RVA-G1 strains reveling an incredible genetic variability among such strains and widespread geographic distribution of its lineages and sublineages (Xin et al., 1993; Jayasinghe and Palombo, 1999; Maunula and von Bonsdorff, 2002; Parra et al., 2005; Arista et al., 2006; Rodríguez-Castillo et al., 2006; Phan et al., 2007; Arora et al., 2009 Arora et al., , 2011 Nagaoka et al., 2012; Zeller et al., 2012) . What is still not clear however is whether such variability will have any impact on the efficacy of RVA vaccines. In a study conducted in the US in 1991-1992 to evaluate the efficacy of two RVA vaccine candidates, a rhesus tetravalent (RRV-TV) and a serotype G1 monovalent (RRV-S1), both contained the RVA/Human-tc/USA/D/1974/ G1P1A[8] strain, Jin et al. (1996) described the occurrence of vaccine breakthrough (i.e., vaccine failure). The authors investigate the possibility that such event was caused by G1 strains that were sufficiently antigenic distinct from the vaccine strain to evade the neutralizing antibodies elicited by the vaccine. The serologic analysis of the G1 breakthrough strains compared to that of Wa strains, whose VP7 protein is nearly identical do the D strain used in the vaccines, revealed that although the pos-immunization neutralizing antibody titers to Wa elicited by vaccination were significantly greater than to the breakthrough strains, this difference did not correlate with lack of protection since similar differences in titers were found using sera from vaccines who either experienced asymptomatic infections or no infections. The authors also analyzed the genetic makeup of the breakthrough strains comparing their sequences to the Wa and D strains and G1 control strains isolated from placebo recipients. They found that all breakthrough and control strains were distinct from Wa and D in antigenically important regions throughout the VP7 protein, including in regions A, B and C. In region A, 10 out of 12 breakthrough strains and 1 out of 3 control strains had a 97-Asp ? Glu change; all strains had a 147-Ser ? Asn in region B. Those specific changes have now been sowed to be important neutralizing site (Aoki et al., 2009 ). The authors concluded that, although the results were not robust enough to support the hypothesis that immune selection of antigenically distinct escape mutants led to vaccine breakthrough, it could not be excluded that the breakthrough could be partially due to antigenic differences in the VP7 proteins of circulating G1strains (Jin et al., 1996) .
Escape mutations selected by neutralizing monoclonal antibodies that recognize VP7 from G1 serotype strains have been identified in amino acid residues 94, 96-100, 104, 145, 147-148, 201, Fig. 1 . Phylogenetic analysis of the partial VP7 nucleotide sequence (49-996) of genotype G1 rotavirus strains. The distances were corrected using the Jukes-Cantor model. The phylogenetic tree was constructed by the neighbor-joining method and statistical support was provided by bootstrapping of 1000 pseudoreplicates. Bootstrap values above 50% are given at branch nodes. Distance scale is in substitutions/site. 211, 213, 217, 221 and 291, all located within regions 7-1 and 7-2 (Kobayashi et al., 1991; Aoki et al., 2009 ). More convincing, serological analysis demonstrate the association of preexisting antibodies that block the amino acid residue 94 (antigenic region A/7-1) of G1 strains with resistance to illness or virus shedding in adults volunteers challenged with a virulent G1 strain (D strain) (Green and Kapikian, 1992) . A similar study demonstrate the association of antibodies that block the amino acid residue 213 (antigenic region C/7-1) of G1strains with protection against illness in children with natural rotavirus infections (O'Ryan et al., 1994) . In this study we observed substitutions in amino acids residues which are located within the antigenic regions A/7-1 (aa 94/Asn ? Ser -all strains belonging to sublineage G1-Ic); region C/7-1 (217/Met ? Thr -all Brazilian lineage G1-I strains analyzed in this study) and; region 7-1 (aa 291/Lys?Arg -all Brazilian lineage G1-I strains analyzed in this study). Although the majority of the amino acid differences were conservative or semi-conservative they were located in the exposed surface of the protein within the VP7 neutralization domain 7-1 which spans the intersubunit boundary and is an immunodominant region. These results suggest that the Brazilian strains, particularly those of lineage G1-I that accumulates mutations in all (lineage Ic) or most (lineages Ia and Ib) of these amino acid residues, could evolve over time into a variant that escape the immune response elicited by the vaccine and consequently cause a vaccine breakthrough. Incidentally, at least partial cross-protection for different lineages has demonstrated for rotaviruses G9 serotype. Hoshino et al. (2004) analyzed the relationship of the phylogenetic lineages to the neutralization specificities of various G9 strains and reported that antibodies raised against lineage 1 G9 strains, represented by the earliest strains recovered in the United States and Japan, efficiently neutralized the contemporary G9 strains from lineages 2 and 3; however, antibodies against the lineage 3 G9 strains did not efficiently neutralize strains belonging to lineage 1.
Yet, it is quite remarkable that the contemporary G1 strains analyzed in the present study, as well as other recent publications (Parra et al., 2005; Arista et al., 2006; Phan et al., 2007; Araújo et al., 2007; Arora et al., 2009; Nagaoka et al., 2012; Zeller et al., 2012) have a genetic makeup different from that of the G1 reference strains Wa isolated in 1974 and the vaccines strains D, isolated in 1974, WI79 isolated in 1983 and 82-12 isolated in 1988. If we considered rotavirus as diverse virus population (Gouvea and Brantly, 1995) it would be possible that these G1 mutant strains represent a non dominant variant on the pool of G1 strain circulating among the human population since earlier 1970s. As the population developed immune response against the dominant strains the mutant G1 strains were able to emerge.
G1 is the most prevalent rotavirus strain around the world (Santos and Hoshino, 2005) . Temporal fluctuation of rotavirus genotypes has been described, with some genotypes such as G2 displaying a circle pattern of 10-years interval (Bishop et al., 1991; Santos and Hoshino, 2005; Leite et al., 2008) . Still, although the frequency of G1 fluctuates it is always present in the population. Perhaps the introduction of new variants could explain the continuous circulation of such strains in the population, as suggested by others (Xin et al., 1993; Jayasinghe and Palombo, 1999; Maunula and von Bonsdorff, 2002; Parra et al., 2005; Arista et al., 2006; Rodríguez-Castillo et al., 2006; Phan et al., 2007; Arora et al., 2009 Arora et al., , 2011 Nagaoka et al., 2012; Zeller et al., 2012) . In this context the continuous emergence of such variant strains would represent a threat for the efficacy of rotavirus vaccine program.
Several studies have shown the rotavirus vaccines efficacy (Vesikari et al., 2006a (Vesikari et al., , 2006b Ruiz-Palacios et al., 2006) . Even though Brazilian contemporary G1 strains are of a different lineage of the vaccine strain currently used in the country, the rotavirus vaccine program has clearly been successful in Brazil (do Carmo et al., 2011). Nevertheless, it is worth to continue monitoring Fig. 2 (continued) rotavirus intragenotype diversity in the post-vaccination era, to understand the impact of variant strains on vaccine effectiveness. Fig. 3 . A 3D model of the VP7 protein of the rotavirus Wa. The regions on VP7, 7-1 (red) and 7-2 (blue), are located at the exposed surfaces of the calcium binding sites, or between domains from the same subunit. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
